July 28, 2014 3:29 AM ET


Company Overview of Genprex, Inc.

Company Overview

Genprex, Inc. is a clinical-stage biopharmaceutical company. It develops molecular therapies for the treatment of cancer. The company offers Oncoprex, a biologic therapy that targets oncogenic pathways to treat tumors and cancer metastases at the molecular level; and GPRX203 that focuses on solid tumor indications. Genprex, Inc. was formerly known as Convergen LifeSciences, Inc. The company was founded in 2009 and is based in Austin, Texas.

6034 West Courtyard Drive

Suite 110

Austin, TX 78730

United States

Founded in 2009



Key Executives for Genprex, Inc.

Executive Chairman
Chairman of Scientific & Medical Advisory Board and Key Medical & Scientific Advisor
Strategic Advisor To The Board of Directors
Compensation as of Fiscal Year 2014.

Genprex, Inc. Key Developments

Genprex Begins Phase II Clinical Trial for Lung Cancer

Genprex, Inc. announced that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex(R) in combination with erlotinib (Tarceva(R)) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways. The trial is significant in that it seeks to determine if patients without the EGFR activating mutation as well as patients with the EGFR activating mutation whose cancer has progressed after erlotinib treatment can benefit from the Oncoprex + erlotinib combination therapy. While erlotinib is a blockbuster drug helping many cancer patients worldwide, research shows that the vast majority of patients who have lung cancers without the activating EGFR mutation are unlikely to benefit from erlotinib. Additionally, many patients with the activating EGFR mutation who respond to erlotinib therapy eventually become resistant to the therapy. The Phase II clinical trial evaluates Oncoprex + erlotinib in late-stage lung cancer patients without an activating EGFR mutation who have received prior chemotherapy or in patients with the activating EGFR mutation whose cancer has progressed after treatment with erlotinib. An initial safety and dose-finding portion of the trial tests four escalating doses of the Oncoprex + erlotinib combination. Approximately 40 patients enrolled in the high dose cohort will be evaluable for efficacy.

Similar Private Companies By Industry

Company Name Region
Tissue Harvest Systems, LLC United States
APT Therapeutics, Inc. United States
Diomics Corporation United States
Etubics Corporation United States
Cardio Technologies, Inc. United States

Recent Private Companies Transactions

Private Placement
December 20, 2013
Private Placement
December 13, 2013

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genprex, Inc., please visit www.genprex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.